Clinical trial · Observational
Estimation of (suPAR) in Chronic Periodontitis With Post-radiotherapy on HNCs Patients
Soluble Urokinase Plasminogen Activator Receptor (suPAR) is a Potential Biomarker of Stage III-IV, Grade C Periodontitis Through the Impact of Post-radiotherapy on Head and Neck Cancer Patients
NCT06529588CI-TRIAL-00079323HNCscompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to improve a soluble urokinase plasminogen activator receptor suPAR is a reliable biomarker of chronic periodontitis and may be replaced in patients with head and neck cancer post-radiotherapy (HNC post-RT).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Periodontitis | — | UNRESOLVED | — |
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Radiotherapy Side Effect | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Head and neck cancer post-radiotherapy
- description
- Head and Neck cancer patients who received radiotherapy (32-35 fractions) exposure (5700-7000 Gys) addition chemotherapy (cisplatin or cetuximab (2-3 dosages).
- interventionNames
- Radiation: Radiation
Primary outcomes (2)
- measure
- Measure of serum suPAR level
- timeFrame
- 6 months
- description
- Measure of serum suPAR level in patients head and neck cancer who received radiotherapy
- measure
- Clinical Periodontal parameters measured
- timeFrame
- 6 months
- description
- Periodontal parameters included (CAL, PI, GBI, PPD) measured by using a millimeter periodontal probe in patients with head and neck cancer who received radiotherapy.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 28 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * A pathologically confirmed malignant neoplasm of HNC (derived from epithelial cells). * Not having received radiation therapy previously. * No distant metastasis. * No history of salivary gland surgery (parotid, submandibular, or sublingual). * A generally satisfactory physical condition with a performance score of 0 to 1 point and a planned survival period of more than a year and scores of 2 higher indicating increasing disability. Exclusion Criteria: * Previous oral disease or salivary gland disease history. * Definitive diagnosis of multiple sclerosis, xerostomia, or systemic disease. * Refusal to participate in the study.
References
Publications (3)
- BACKGROUNDLalla RV, Treister NS, Sollecito TP, Schmidt BL, Patton LL, Helgeson ES, Lin A, Rybczyk C, Dowsett R, Hegde U, Boyd TS, Duplinsky TG, Brennan MT. Radiation therapy for head and neck cancer leads to gingival recession associated with dental caries. Oral Surg Oral Med Oral Pathol Oral Radiol. 2022 May;133(5):539-546. doi: 10.1016/j.oooo.2022.01.016. Epub 2022 Jan 31. PMID 35304084
- RESULTGasparoni LM, Alves FA, Holzhausen M, Pannuti CM, Serpa MS. Periodontitis as a risk factor for head and neck cancer. Med Oral Patol Oral Cir Bucal. 2021 Jul 1;26(4):e430-e436. doi: 10.4317/medoral.24270. PMID 33340075
- DERIVEDAl-Kubaisi AA, Ghazi MA, Majeed NS, Aldelaimi ER, Enezei HH. Soluble urokinase plasminogen activator receptor (suPAR) is a potential biomarker of stage III-IV, grade C periodontitis through the impact of post-radiotherapy on head and neck cancer patients. BMC Oral Health. 2024 Sep 27;24(1):1144. doi: 10.1186/s12903-024-04801-w. PMID 39334335